Table 2

Neutralization of HIV-2 envelopes with 5 human HIV-2 monoclonal antibodies

EnvMean IC50 (μg/ml)aPlasma neutralization titerb
1.7A (V4 dependent)6.10F (V3)6.10B (CD4 BSc)1.4B (overlaps V3)1.4H (CD4i)
7312A0.080.0040.10.038>10d2.8 × 105H
ROD ARe>10>10>10>10>1032Hf
CA316.90.180.010.19>10>107.3 × 105
CA319.7>100.0150.260.050.025.1 × 105
CA330.5>100.010.1650.180.1755.7 × 104
CA381.40.0250.010.07>100.44.4 × 105
CA4401.14.590.010.170.4152.52.0 × 105
CA4153.9>100.010.0951.020.0157.2 × 105
CA7205.80.0150.00750.180.020.0152.5 × 105H
CA4145.130.170.0060.20.180.023.8 × 105
CA4291.20.540.0060.1550.1150.0251.6 × 104
CA409.14R>10>10>10>10>1064
CA4205.1R>10>10>10>10>10713
CA4205.8R>10>10>10>10>1087
CA4137.6>100.0150.090.660.188.6 × 104
CA4137.2>100.0070.0950.450.0451.4 × 105
CA4137.19R>10>10>10>10>10<20
CA4137.21>100.010.070.30.0351.7 × 105
CA4206.6>100.030.650.440.15.6 × 104
CA4206.7>100.010.20.60.171.7 × 105
CA4206.13>100.041.010.950.219.8 × 104
CA4206.5R>10>10>10>10>10111
CA4206.14R>10>10>10>10>10314
VSV>10>10>10>10>10
  • a Values given are the mean IC50s from two or three separate experiments.

  • b Values for neutralizing antibody titers are reciprocal plasma autologous titers unless otherwise stated.

  • c CD4 BS, anti-CD4 binding site.

  • d Bold data indicate envelope-MAb combinations where no neutralization was observed.

  • e R, envelope resistant to autologous and/or heterologous plasma neutralization.

  • f H, median reciprocal heterologous neutralizing antibody titer (against 40 subject plasma samples).